Moderna Not Immune To COVID-19 Effects On Trials
US Lockdown Hits Rare Disease Trials
Company suspends enrolment to trials as coronavirus travel restrictions bite.
You may also be interested in...
Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.